Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA; National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium.

J Natl Cancer Inst. 2007 Sep 5;99(17):1335-9. Epub 2007 Aug 14. Erratum in: J Natl Cancer Inst. 2007 Oct 3;99(19):1493.

PMID:
17698950
2.

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.

J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61. Epub 2007 Jul 24.

PMID:
17652280
3.

The decrease in breast-cancer incidence in 2003 in the United States.

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA.

N Engl J Med. 2007 Apr 19;356(16):1670-4.

4.

Breast tumours following combined hormone replacement therapy express favourable prognostic factors.

Borgquist S, Anagnostaki L, Jirström K, Landberg G, Manjer J.

Int J Cancer. 2007 May 15;120(10):2202-7.

5.

Safety of hormone therapy after breast cancer: a qualitative systematic review.

Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S.

Hum Reprod. 2007 Feb;22(2):616-22. Epub 2006 Oct 18. Review.

PMID:
17050551
6.

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators.

JAMA. 2006 Apr 12;295(14):1647-57.

PMID:
16609086
7.

Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis.

Fletcher AS, Erbas B, Kavanagh AM, Hart S, Rodger A, Gertig DM.

Breast. 2005 Jun;14(3):192-200. Epub 2005 Jan 8.

PMID:
15927828
8.

Histopathologic indicators of breast cancer biology: insights from population mammographic screening.

Webster LR, Bilous AM, Willis L, Byth K, Burgemeister FC, Salisbury EL, Clarke CL, Balleine RL.

Br J Cancer. 2005 Apr 25;92(8):1366-71.

9.
10.

Molecular evolution of breast cancer.

Simpson PT, Reis-Filho JS, Gale T, Lakhani SR.

J Pathol. 2005 Jan;205(2):248-54. Review.

PMID:
15641021
11.

Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics.

Lacroix M, Toillon RA, Leclercq G.

Endocr Relat Cancer. 2004 Sep;11(3):497-522. Review.

12.

Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.

Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E.

Br J Cancer. 2004 Aug 16;91(4):644-50.

13.

Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.

Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R.

Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81.

14.

Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.

Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA.

J Clin Oncol. 2003 Dec 1;21(23):4314-21.

PMID:
14645420
15.

Duration of hormone replacement therapy, breast tumour size and grade in a screening programme.

Gertig DM, Erbas B, Fletcher A, Amos A, Kavanagh AM.

Breast Cancer Res Treat. 2003 Aug;80(3):267-73.

PMID:
14503799
16.

Breast cancer and hormone-replacement therapy in the Million Women Study.

Beral V; Million Women Study Collaborators.

Lancet. 2003 Aug 9;362(9382):419-27. Erratum in: Lancet. 2003 Oct 4;362(9390):1160.

PMID:
12927427
17.

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators.

JAMA. 2003 Jun 25;289(24):3243-53.

PMID:
12824205
19.

Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users.

Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G, Veronesi U.

Ann Surg Oncol. 2002 Apr;9(3):266-71.

PMID:
11923133
20.

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

Ross RK, Paganini-Hill A, Wan PC, Pike MC.

J Natl Cancer Inst. 2000 Feb 16;92(4):328-32.

PMID:
10675382

Supplemental Content

Support Center